Production (Stage)
Relmada Therapeutics, Inc.
RLMD
$0.7085
-$0.0415-5.53%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 34.30M | 37.72M | 41.72M | 42.10M | 46.29M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.12M | 83.89M | 91.64M | 91.33M | 98.54M |
| Operating Income | -79.12M | -83.89M | -91.64M | -91.33M | -98.54M |
| Income Before Tax | -75.71M | -79.98M | -86.49M | -86.76M | -94.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -75.71 | -79.98 | -86.49 | -86.76 | -94.30 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -75.71M | -79.98M | -86.49M | -86.76M | -94.30M |
| EBIT | -79.12M | -83.89M | -91.64M | -91.33M | -98.54M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.50 | -2.65 | -2.87 | -2.88 | -3.13 |
| Normalized Basic EPS | -1.58 | -1.67 | -1.81 | -1.80 | -1.94 |
| EPS Diluted | -2.51 | -2.65 | -2.87 | -2.88 | -3.13 |
| Normalized Diluted EPS | -1.58 | -1.67 | -1.81 | -1.80 | -1.94 |
| Average Basic Shares Outstanding | 120.93M | 120.65M | 120.58M | 120.50M | 120.43M |
| Average Diluted Shares Outstanding | 120.93M | 120.65M | 120.58M | 120.50M | 120.43M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |